VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-14.66%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$242M
AUM Growth
+$242M
(-20%)
Cap. Flow
-$5.92M
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
99.81%
Holding
11
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$4.8M |
| 2 |
CRISPR Therapeutics
CRSP
|
$1.12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.71B
| $55.8M | 23.11% | 498,558 -10,000 | -2% | -$1.12M |
|
2
Passage Bio
PASG
$22.7M
| $49.4M | 20.45% | 4,959,769 | – | – |
|
|
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $43.3M | 17.91% | 4,005,894 -444,744 | -10% | -$4.8M |
|
4
Aligos Therapeutics
ALGS
$73.3M
| $36M | 14.9% | 2,320,381 | – | – |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $17.3M | 7.15% | 820,720 | – | – |
|
6
Akero Therapeutics
AKRO
$3.74B
| $13.8M | 5.72% | 617,727 | – | – |
|
7
Adverum Biotechnologies
ADVM
$64.6M
| $11M | 4.55% | 5,068,233 | – | – |
|
8
Aprea Therapeutics
APRE
$9.09M
| $6.44M | 2.67% | 1,259,662 | – | – |
|
|
FLXN
9
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $6.1M | 2.53% | 1,000,000 | – | – |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $1.99M | 0.82% | 543,753 | – | – |
|
|
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
| $454K | 0.19% | 101,855 | – | – |
|